Publicaciones en colaboración con investigadores/as de Yale School of Medicine (2)

2023

  1. Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: Multicenter, phase Ib dose escalation and expansion study

    International Journal of Gynecological Cancer, Vol. 33, Núm. 4, pp. 562-570

2019

  1. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

    Annals of Oncology, Vol. 30, Núm. 7, pp. 1080-1087